Charles M. Beasley, Jr., M.D. | Psychiatrist.com

Original Research

Early Symptomatic Worsening During Treatment With Fluoxetine in Major Depressive Disorder: Prevalence and Implications

January 15, 2007

Cristina Cusin, Maurizio Fava, Jay D. Amsterdam, et al

Original Research

Analysis of the QTc Interval During Olanzapine Treatment of Patients With Schizophrenia and Related Psychosis

March 1, 2001

Jöerg Czekalla, Charles M. Beasley, Jr., Mary Anne Dellva, et al

Article

Cardiac Safety Parameters of Olanzapine: Comparison With Other Atypical and Typical Antipsychotics

February 1, 2001

Jöerg Czekalla, Sara Kollack-Walker, Charles M. Beasley, Jr.

Original Research

Efficacy, Adverse Events, and Treatment Discontinuations in Fluoxetine Clinical Studies of Major Depression: A Meta-Analysis of the 20-mg/day Dose

October 31, 2000

Charles M. Beasley, Jr., Mary E. Nilsson, Stephanie C. Koke, et al

Original Research

Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression

July 31, 2000

Patrick J. McGrath, Jonathan W. Stewart, Eva Petkova, et al

Original Research

Changes in Adverse Events Reported by Patients During 6 Months of Fluoxetine Therapy

June 30, 1999

John Zajecka, Jay D. Amsterdam, Frederic M. Quitkin, et al

Original Research

Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia

May 15, 1997

Pierre V. Tran, Mary Anne Dellva, Gary D. Tollefson, et al

Article

Safety of Olanzapine

March 1, 1997

Charles M. Beasley, Jr., Gary D. Tollefson, Pierre V. Tran

Article

Efficacy of Olanzapine: An Overview of Pivotal Clinical Trials

February 1, 1997

Charles M. Beasley, Jr., Gary D. Tollefson, Pierre V. Tran